Navigation Links
Biotech Cools Off in August But Capital Markets Remain Positive
Date:9/1/2009

SAN FRANCISCO, Sept. 1 /PRNewswire/ -- Just as biotech was "hot" in July it was a different story in August as the Burrill Biotech Select Index suffered from the summer "blahs" and posted a lackluster performance to close down 1.1 percent. The broader markets, on the other hand, continued their upward swing with the Dow closing the month up a healthy 3.5 percent and the Nasdaq closing up 1.5 percent.

Investors were, however, reminded on the last day of the trading month, that despite Federal Reserve Chairman Ben Bernanke's assessment that the economy is on the verge of recovery, there is still some way to go yet. The Dow and Nasdaq dropped 0.5 and 1 percent respectively because a sharp drop in Chinese equities added to concerns about the relative strength of the global economy's recovery.

"The final quarter of the year is traditionally one of biotech's best," said G. Steven Burrill, CEO, Burrill & Company, a San Francisco based global leader in life sciences with activities in Private Equity, Venture Capital, Merchant Banking and Media, "and we will likely see, despite the market uncertainties, the industry build on its momentum gained during the past several months.

"Although biotech's year-to-date performance lags the general markets there have been some encouraging signs that investors are coming back spurred in July by the market performances of companies such as Human Genome Sciences and Targacept and the marquee acquisition of Medarex by Bristol-Myers Squibb. In addition, we did see an IPO get out the door in August. Cumberland Pharmaceuticals raised $85 million by offering 5,000,000 shares at $17.00, below the expected range of $19.00 to $21.00. The specialty pharmaceuticals company has products on the market, including a new injectable treatment for pain and fever, which is one of the reasons why the deal got done," noted Burrill.

"The Cu
'/>"/>

SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes
2. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
3. Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent
4. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
5. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
6. Malaysian Biotechnology Sector
7. PCI Biotech Commences Phase I/II Trials of Amphinex(R)
8. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
9. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
10. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
11. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... the atrial fibrillation drug market will increase more ... $6.1 billion in 2018 in the United States, ... Japan. ,, The new Pharmacor report entitled ...
(Date:12/11/2009)... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: ... of its previously announced public offering have exercised ... 2,250,000 shares of common stock at the public ... exercise of the option increases the size of ... of common stock. Dendreon expects to receive ...
(Date:12/11/2009)... 11 Ambit Biosciences Corporation announced today the ... D. Anderson Cancer Center of the first patient in ... E fficacy) Phase 2 pivotal trial in ... AC220 is a novel, orally available, potent and ... a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE ...
(Date:12/11/2009)... CALGARY, Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... today announced the appointment of Dr. Alan Warrander ... Licensing and Business Development. ,, "Dr. Warrander will ... licensing strategy for REOLYSIN(R)," said Dr. Brad Thompson, ... agreement on the design of a Phase 3 ...
Breaking Biology Technology:The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
... Parion Sciences, Inc. today announced,that its partner, Gilead ... a Phase I,clinical trial of GS9411 in healthy ... investigational compound. GS9411 is designed to increase,airway ... Previously known as,P-680, GS9411 is an epithelial sodium ...
... its revolutionary Trusted LASIK Surgeons directory service and website ... resource for consumers seeking to improve their vision. What ... unique screening process ensuring that only those who are ... eye surgery in the United States are listed. ...
... the well-known dangers of first- and secondhand smoke, an estimated ... Exposure of a developing baby to harmful cigarette byproducts ... year and poses a significant health care burden. , Now, ... researchers has completed a global assessment of newborns, umbilical cord ...
Other Biology Technology:Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 2Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 3Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 2Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 3Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 4Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 5Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 6Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 7Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4
(Date:12/15/2009)... is a standard laboratory model organism, but there ... to analyze blood and blood-forming tissues in this ... and easy-to-use laboratory resources from Cold Spring Harbor ... Hematology features step-by-step protocols for the preparation, ... marrow, and other hematopoietic tissues in the mouse. ...
(Date:12/14/2009)... in a freeze-tolerant Alaska beetle able to survive temperatures ... biological antifreezes that contain protein, this new molecule, called ... of a sugar and a fatty acid and may ... , "The most exciting part of this discovery ... of antifreeze that may work in a different location ...
(Date:12/14/2009)... The most comprehensive study to date of the proteins ... may provide important clues to how similar regeneration could ... School of Science at Indiana University-Purdue University Indianapolis and ... limbs of axolotls, a type of salamander that has ... level of amputation, with the hope that this knowledge ...
Breaking Biology News(10 mins):New source of classical techniques for blood-based studies in the laboratory mouse 2Scientists isolate new antifreeze molecule in Alaska beetle 2IUPUI researchers tackle protein mechanisms behind limb regeneration 2IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests 55679 1IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests 55679 2Former Veterans Affairs Secretary Joins Integrated Medical Systems Advisory Board 55676 1Former Veterans Affairs Secretary Joins Integrated Medical Systems Advisory Board 55676 2Former Veterans Affairs Secretary Joins Integrated Medical Systems Advisory Board 55676 380 Million European Runners Reveal Their Reasons to Run 55673 180 Million European Runners Reveal Their Reasons to Run 55673 280 Million European Runners Reveal Their Reasons to Run 55673 3
... respected as a world leader in scientific research, has ... being filled by foreign guest workers, but recent regulations ... S. have created a need for a new pool ... his colleagues at Texas A&M UniversityKingsville, the University of ...
... vegetables and fruits, color is one of the best ... color plays an important role in the business of ... example, color and color uniformity contribute directly to quality ... YSD, a ripening disorder that results in blotchy discoloration ...
... almost half as much particulate pollution into the air ... a new study. Ship pollutants affect both the Earth,s ... , The study is the first to provide ... air particle pollution based on direct measurements of emissions. ...
Other Biology News:Science internships attract students to research careers 2Color test enhances tomato analyzer software 2Commercial ships spew half as much particulate pollution as world's cars 2Commercial ships spew half as much particulate pollution as world's cars 3
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
Request Info...
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
Biology Products: